Monte Rosa Therapeutics (GLUE) Share-based Compensation (2020 - 2026)

Monte Rosa Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $5.9 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 12.29% year-over-year to $5.9 million; the TTM figure through Mar 2026 stood at $19.5 million (up 5.2% YoY), while the FY2025 annual figure was $18.9 million, up 4.08% from the prior year.
• Share-based Compensation was $5.9 million for Q1 2026 at Monte Rosa Therapeutics, up from $4.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $5.9 million in Q1 2026 to a low of $2.3 million in Q1 2022.
• Historically, Share-based Compensation has averaged $4.2 million across 5 years, with a median of $4.3 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation jumped 793.25% in 2022, then decreased 4.16% in 2024.
• A 5-year view of Share-based Compensation shows it stood at $3.3 million in 2022, then grew by 22.49% to $4.1 million in 2023, then climbed by 9.7% to $4.5 million in 2024, then decreased by 3.58% to $4.3 million in 2025, then jumped by 38.06% to $5.9 million in 2026.
• The last three Share-based Compensation figures came in at $5.9 million (Q1 2026), $4.3 million (Q4 2025), and $4.4 million (Q3 2025), per Business Quant data.